October 23, 2023 01:35 PM EDT

Unapproved uses of approved drugs: FDA lays out pharma considerations for informing providers

Lia DeGroot

The FDA on Monday published another draft guidance on drug companies’ communications with healthcare providers regarding the unapproved use of approved …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Unapproved uses of approved drugs: FDA lays out pharma considerations for informing providers

Lia DeGroot

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Charles River to close ‘15 smaller sites’ as demand for early research declines

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Un­ap­proved us­es of ap­proved drugs: FDA lays out phar­ma con­sid­er­a­tions for in­form­ing providers

Lia DeGroot

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Charles Riv­er to close ‘15 small­er sites’ as de­mand for ear­ly re­search de­clines

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Unapproved uses of approved drugs: FDA lays out pharma considerations for informing providers

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Charles River to close ‘15 smaller sites’ as demand for early research declines

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks